Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Sarcopenia is a muscle loss syndrome known as a risk factor of various carcinomas. The impact of sarcopenia and sarcopenia-related inflammatory/nutritional markers in metastatic urothelial carcinoma (mUC) treated with pembrolizumab was unknown, so this retrospective study of 27 patients was performe...

Full description

Bibliographic Details
Main Authors:	Takuto Shimizu, Makito Miyake, Shunta Hori, Kazuki Ichikawa, Chihiro Omori, Yusuke Iemura, Takuya Owari, Yoshitaka Itami, Yasushi Nakai, Satoshi Anai, Atsushi Tomioka, Nobumichi Tanaka, Kiyohide Fujimoto
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Diagnostics
Subjects:	immune checkpoint inhibitor Pembrolizumab Sarcopenia psoas muscle mass index neutrophil-to-lymphocyte ratio prognostic nutritional index
Online Access:	https://www.mdpi.com/2075-4418/10/5/310

Similar Items

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder
by: Makito Miyake, et al.
Published: (2017-03-01)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
by: Hiroyuki Nishiyama, et al.
Published: (2023-06-01)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
by: Kyotaro Fukuta, et al.
Published: (2021-09-01)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01)

A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE Trial
by: Makito Miyake, et al.
Published: (2024-07-01)

Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
by: Manabu Hayata, et al.
Published: (2020-07-01)

Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
by: Hiroki Takeda, et al.
Published: (2022-03-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01)

Initial experience of complete laparoscopic radical nephroureterectomy combined with transvesical laparoscopic excision of distal ureter in patients with upper urinary tract cancer
by: Makito Miyake, et al.
Published: (2020-05-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma
by: Risa Tomioka-Inagawa, et al.
Published: (2022-07-01)

The role of sarcopenia in fragility fractures of the pelvis – is sarcopenia an underestimated risk factor?
by: Olivia Mair, et al.
Published: (2024-05-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer
by: Nobutaka Nishimura, et al.
Published: (2024-01-01)

Living‐donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome
by: Nobutaka Nishimura, et al.
Published: (2020-11-01)

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
by: Sivraj Muralikrishnan, et al.
Published: (2020-01-01)

Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma
by: Takuto Shimizu, et al.
Published: (2020-03-01)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
by: Hiroshi Fukushima, et al.
Published: (2020-11-01)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
by: Katsuhiro Ito, et al.
Published: (2023-02-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report
by: Israa Mahmood, PharmD, et al.
Published: (2021-01-01)

Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
by: Tulika Chatterjee, et al.
Published: (2022-01-01)

A comprehensive investigation of nutritional status and psoas muscle mass in predicting five-year survival in patients with liver transplant
by: Ya-Tzu Tsao, et al.
Published: (2022-07-01)

Pembrolizumab-induced necrotizing diaphragmatic myositis
by: David Rodríguez-Plaza, et al.
Published: (2024-06-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

Reply to “Predictors of Recurrence for T3a RCC: A Recurring Conundrum”
by: Makito Miyake, et al.
Published: (2020-11-01)

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
by: Andong Li, et al.
Published: (2024-09-01)

Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors
by: Makito Miyake, et al.
Published: (2024-10-01)

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022-10-01)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
by: Akiko Ishii, et al.
Published: (2020-06-01)

Assessment of Psoas Muscle Index in Middle-Aged Type 2 Diabetes Patients: Impact of Insulin Therapy on Sarcopenia
by: Ismail Taskent, et al.
Published: (2024-07-01)

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report
by: Yasumiko Jodai, et al.
Published: (2023-01-01)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
by: Furubayashi N, et al.
Published: (2022-05-01)

Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
by: Francesca Zacchi, et al.
Published: (2025-02-01)

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
by: Daiki Ikarashi, et al.
Published: (2020-09-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)